1 research outputs found
Prospective Investigation of the Performance of 2 Gamma-Hydroxybutyric Acid Tests: DrugCheck GHB Single Test and Viva-E GHB Immunoassay
Background: Gamma-hydroxybutyric acid (GHB) is a recreational
drug with central nervous system depressing effects that is often abused.
A urine GHB point-of-care test can be of great diagnostic value. The
objective of this prospective study was to determine the performance of
the new DrugCheck GHB Single Test and the Viva-E GHB
immunoassay for urine samples in emergency department patients.
Methods: Patients presented to the emergency department of the
OLVG hospital in Amsterdam with a Glasgow Coma Scale score
,15 and potential drug of abuse intoxication were included in the
study. Between June 2016 and October 2017, 375 patients were
included. Using the DrugCheck GHB Single Test (Express Diagnostics Int’l, Blue Earth, MN) and the Viva-E GHB immunoassay (Siemens Healthineers, The Hague, the Netherlands), patients’ urine
samples were tested for GHB (cutoff for a positive result, 10 or 50
mcg/mL GHB). To ensure quality, the results obtained were compared with those generated using a validated gas chromatography
method. The tests were considered reliable if specificity and sensitivity were both .90%. Possible cross-reactivity with ethanol was
investigated by analyzing ethanol concentrations in patients’
samples.
Results: Seventy percentage of the included patients was men, and
the median age was 34 years old. The DrugCheck GHB Single
Test’s specificity and sensitivity were 90.0% a